Practice Resource

PARP Inhibitor Outcomes in Cancer: Focus on Biomarkers of Homologous Recombination Repair

Published: December 1, 2023
magnifying glass viewing DNA double helix

The rapid pace in the evolution of knowledge regarding how cancer develops, and best approaches to treatment, is a challenge for the medical community. This educational activity will review the deleterious effects of DNA damage, specifically the science of homologous recombination deficiency and how it contributes to the development of cancer. Learn about approved and expanded indications for poly ADP-ribose polymerase (PARP) inhibitors, including evidence for their use based on biomarkers, efficacy, and safety data. The activity will include real-life case scenarios demonstrating how genetic testing data can be used to develop treatment plans.

Join us Monday, Dec. 4, from 11:30 a.m. to 1 p.m. PT, for the Midday Symposium Optimizing PARP Inhibitor Outcomes in Cancer Therapy: Focus on Biomarkers of Homologous Recombination Repair, held in room 157, 100 Level, Anaheim Convention Center North. Earn 1.5 hours of CE credit.

The Midday Symposium will also be broadcast as a live webinar for CE credit. If you have colleagues at home who are interested in this topic, encourage them to register for the webinar.

This activity is provided by ASHP and supported by educational grants from AstraZeneca and Merck.

Posted December 1, 2023

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information